Multinational prospective study of incidence and risk factors for central-line–associated bloodstream infections in 728 intensive care units of 41 Asian, African, Eastern European, Latin American, and Middle Eastern countries over 24 years

Author:

Rosenthal Victor DanielORCID,Yin RuijieORCID,Myatra Sheila NainanORCID,Memish Ziad A.ORCID,Rodrigues Camilla,Kharbanda Mohit,Valderrama-Beltran Sandra Liliana,Mehta YatinORCID,Afeef Al-Ruzzieh Majeda,Aguirre-Avalos GuadalupeORCID,Guclu Ertugrul,Gan Chin SengORCID,Jiménez Alvarez Luisa Fernanda,Chawla Rajesh,Hlinkova SonaORCID,Arjun RajalakshmiORCID,Agha Hala Mounir,Zuniga Chavarria Maria Adelia,Davaadagva Narangarav,Lai Yin Hoong,Gomez Katherine,Aguilar-de-Moros DaisyORCID,Tai Chian-WernORCID,Sassoe Gonzalez Alejandro,Aguilar Moreno Lina Alejandra,Sandhu KavitaORCID,Janc JarosławORCID,Aleman Bocanegra Mary Cruz,Yildizdas Dincer,Cano Medina Yuliana AndreaORCID,Villegas Mota Maria Isabel,Omar Abeer Aly,Duszynska WieslawaORCID,El-Kholy Amani AliORCID,Alkhawaja Safaa AbdulazizORCID,Florin George Horhat,Medeiros Eduardo AlexandrinoORCID,Tao Lili,Tumu Nellie,Elanbya May Gamar,Dongol Reshma,Mioljević Vesna,Raka Lul,Dueñas Lourdes,Carreazo Nilton YhuriORCID,Dendane Tarek,Ikram Aamer,Kardas Tala,Petrov Michael M.ORCID,Bouziri Asma,Viet-Hung Nguyen,Belskiy VladislavORCID,Elahi NaheedORCID,Salgado Estuardo,Jin Zhilin

Abstract

AbstractObjective:To identify central-line (CL)–associated bloodstream infection (CLABSI) incidence and risk factors in low- and middle-income countries (LMICs).Design:From July 1, 1998, to February 12, 2022, we conducted a multinational multicenter prospective cohort study using online standardized surveillance system and unified forms.Setting:The study included 728 ICUs of 286 hospitals in 147 cities in 41 African, Asian, Eastern European, Latin American, and Middle Eastern countries.Patients:In total, 278,241 patients followed during 1,815,043 patient days acquired 3,537 CLABSIs.Methods:For the CLABSI rate, we used CL days as the denominator and the number of CLABSIs as the numerator. Using multiple logistic regression, outcomes are shown as adjusted odds ratios (aORs).Results:The pooled CLABSI rate was 4.82 CLABSIs per 1,000 CL days, which is significantly higher than that reported by the Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN). We analyzed 11 variables, and the following variables were independently and significantly associated with CLABSI: length of stay (LOS), risk increasing 3% daily (aOR, 1.03; 95% CI, 1.03–1.04; P < .0001), number of CL days, risk increasing 4% per CL day (aOR, 1.04; 95% CI, 1.03–1.04; P < .0001), surgical hospitalization (aOR, 1.12; 95% CI, 1.03–1.21; P < .0001), tracheostomy use (aOR, 1.52; 95% CI, 1.23–1.88; P < .0001), hospitalization at a publicly owned facility (aOR, 3.04; 95% CI, 2.31–4.01; P <.0001) or at a teaching hospital (aOR, 2.91; 95% CI, 2.22–3.83; P < .0001), hospitalization in a middle-income country (aOR, 2.41; 95% CI, 2.09–2.77; P < .0001). The ICU type with highest risk was adult oncology (aOR, 4.35; 95% CI, 3.11–6.09; P < .0001), followed by pediatric oncology (aOR, 2.51;95% CI, 1.57–3.99; P < .0001), and pediatric (aOR, 2.34; 95% CI, 1.81–3.01; P < .0001). The CL type with the highest risk was internal-jugular (aOR, 3.01; 95% CI, 2.71–3.33; P < .0001), followed by femoral (aOR, 2.29; 95% CI, 1.96–2.68; P < .0001). Peripherally inserted central catheter (PICC) was the CL with the lowest CLABSI risk (aOR, 1.48; 95% CI, 1.02–2.18; P = .04).Conclusions:The following CLABSI risk factors are unlikely to change: country income level, facility ownership, hospitalization type, and ICU type. These findings suggest a focus on reducing LOS, CL days, and tracheostomy; using PICC instead of internal-jugular or femoral CL; and implementing evidence-based CLABSI prevention recommendations.

Publisher

Cambridge University Press (CUP)

Subject

Infectious Diseases,Microbiology (medical),Epidemiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3